Clinical significance of a microRNA signature for the identification and predicting prognosis in colorectal cancers with mucinous differentiation
Por:
Ruiz-Banobre, J, Roy, R, Fernandez, M, Murcia, O, Jover, R, Pera, M, Balaguer, F, Lopez-Lopez, R and Goel, A
Publicada:
1 nov 2020
Resumen:
Accumulating evidence supports the fact that the mere presence of mucinous differentiation in colorectal cancer (CRC), rather than its proportion, is a more accurate representative of a particular CRC subtype with distinct clinical and molecular features. In addition, the prognostic significance of the mucinous carcinoma (MC) subtype remains poorly understood and biomarkers have been barely explored in this disease. Herein, we have performed a systematic and comprehensive analysis in MCs and non-MCs and identified a panel of microRNAs (miRNAs) that are differentially expressed between these two subtypes of CRC. Next, we interrogated their clinical significance and demonstrated their robust diagnostic and prognostic clinical ability in CRCs with mucinous differentiation. Finally, we established an integrative risk-assessment model by combining the miRNA-based risk scores together with TNM staging, which was a superior predictor of prognosis in mucinous CRC patients. Collectively, we report a novel miRNA biomarker panel for the identification and predicting survival in CRC patients with mucinous differentiation.
Filiaciones:
Ruiz-Banobre, J:
Univ Clin Hosp Santiago de Compostela, Med Oncol Dept, CIBERONC, Santiago De Compostela 15706, Spain
Univ Clin Hosp Santiago de Compostela, Hlth Res Inst Santiago IDIS, CIBERONC, Translat Med Oncol Grp Oncomet, Santiago De Compostela 15706, Spain
Baylor Univ, Ctr Gastrointestinal Res, Med Ctr, Dallas, TX 75246 USA
Baylor Univ, Ctr Translat Genom & Oncol, Med Ctr, Baylor Scott & White Res Inst, Dallas, TX 75246 USA
Baylor Univ, Charles A Sammons Canc Ctr, Med Ctr, Dallas, TX 75246 USA
Roy, R:
Baylor Univ, Ctr Gastrointestinal Res, Med Ctr, Dallas, TX 75246 USA
Baylor Univ, Ctr Translat Genom & Oncol, Med Ctr, Baylor Scott & White Res Inst, Dallas, TX 75246 USA
Baylor Univ, Charles A Sammons Canc Ctr, Med Ctr, Dallas, TX 75246 USA
:
Alicante Univ, Alicante Inst Hlth & Biomed Res ISABIAL, Lab Invest, Gen Hosp, Alicante 03010, Spain
:
Alicante Univ, Alicante Inst Hlth & Biomed Res ISABIAL, Lab Invest, Gen Hosp, Alicante 03010, Spain
Alicante Univ, Alicante Inst Hlth & Biomed Res ISABIAL, Digest Med Dept, Gen Hosp, Alicante 03010, Spain
:
Alicante Univ, Alicante Inst Hlth & Biomed Res ISABIAL, Lab Invest, Gen Hosp, Alicante 03010, Spain
Alicante Univ, Alicante Inst Hlth & Biomed Res ISABIAL, Digest Med Dept, Gen Hosp, Alicante 03010, Spain
Pera, M:
Hosp del Mar IMIM, Dept Surg, Sect Colon & Rectal Surg, Barcelona 08003, Spain
Balaguer, F:
Hosp Clin Barcelona, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Gastroenterol, Barcelona 08036, Spain
Lopez-Lopez, R:
Univ Clin Hosp Santiago de Compostela, Med Oncol Dept, CIBERONC, Santiago De Compostela 15706, Spain
Univ Clin Hosp Santiago de Compostela, Hlth Res Inst Santiago IDIS, CIBERONC, Translat Med Oncol Grp Oncomet, Santiago De Compostela 15706, Spain
Goel, A:
Baylor Univ, Ctr Gastrointestinal Res, Med Ctr, Dallas, TX 75246 USA
Baylor Univ, Ctr Translat Genom & Oncol, Med Ctr, Baylor Scott & White Res Inst, Dallas, TX 75246 USA
Baylor Univ, Charles A Sammons Canc Ctr, Med Ctr, Dallas, TX 75246 USA
City Hope Comprehens Canc Ctr, Dept Mol Diagnost & Expt Therapeut, Beckman Res Inst, 1218 S Fifth Ave,Suite 2226, Monrovia, CA 91016 USA
Green Published
|